Treatment of vascular retinopathies with Pycnogenol.
The aim of our study was to investigate the effects of Pycnogenol on the progression of diabetic retinopathy and other vascular retinal disorders. The study consisted of a double-blind phase in which 20 patients were recruited and randomly treated with placebo or Pycnogenol (50 mg x 3/day for 2 months) and an open phase in which another 20 patients were treated with Pycnogenol at the same dose schedule. In total, 40 patients with diabetes, atherosclerosis and other vascular diseases involving the retina were enrolled; 30 of them were treated with Pycnogenol and 10 with placebo. The results demonstrated a beneficial effect of Pycnogenol on the progression of retinopathy. Without any treatment (placebo) the retinopathy progressively worsened during the trial and the visual acuity significantly decreased; on the contrary, the Pycnogenol-treated patients showed no deterioration of retinal function and a significant recovery of visual acuity was also obtained. The fluorangiography showed an improvement of retinal vascularization and a reduced endothelial permeability and leakage in the Pycnogenol, but not in the placebo-treated, patients. The ophthalmoscopy and the electroretinogram (ERG) also confirmed the beneficial effects of Pycnogenol. The mechanism of action of Pycnogenol may be related to its free radical (FR) scavenging, anti-inflammatory and capillary protective activities. It has been suggested that Pycnogenol may bind to the blood vessel wall proteins and mucopolysaccharides and produce a capillary 'sealing' effect, leading to a reduced capillary permeability and oedema formation.
Spadea
L
L
Dipartimento di Discipline Chirurgiche, Cattedra di Clinica Oculistica, Facoltà di Medicina e Chirurgia, Via Vetoio, Coppito 2, L'Aquila, Italy.
Balestrazzi
E
E
D003930:Diabetic Retinopathy / Q000188:drug therapy; D004311:Double-Blind Method; D004596:Electroretinography; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D005451:Fluorescein Angiography; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009887:Ophthalmoscopy; D010936:Plant Extracts; D012164:Retinal Diseases / Q000188:drug therapy*; D016896:Treatment Outcome; D014792:Visual Acuity
D005419:Flavonoids; D016166:Free Radical Scavengers; D010936:Plant Extracts; C024070:pycnogenols